Search
forLearn
5 / 801 resultslearn Ethinylestradiol
learn Naltrexone
learn Setipiprant
learn Dextran
Research
5 / 1000+ resultsresearch Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
GLP-1 receptor agonists help women with PCOS lose weight and improve health, but more research is needed on long-term effects.
research Associations Between GLP‐1 Receptor Agonists and Alopecia: A Multi‐Centre Retrospective Analysis and Public Interest Trends
GLP-1 receptor agonists may increase the risk of a specific type of hair loss called androgenetic alopecia.
research The Clinical Center’s Blood Glucose Management Service
The Blood Glucose Management Service improved patient safety and outcomes in managing blood sugar in hospitalized patients.
research A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome
Liraglutide caused significant weight loss in some obese women with PCOS, especially those with severe obesity and insulin resistance.
research Role of Sodium–Glucose Cotransporter-2 Inhibitors in Managing Polycystic Ovary Syndrome: A Systematic Review
SGLT2 inhibitors may help manage PCOS symptoms effectively.
Community Join
5 / 1000+ resultscommunity Exosomes injections
User tried finasteride and minoxidil for hair loss, now considering exosomes injections. Will update on results after appointment.
community Ruxolitinib - Start of a case study
The conversation is about a user trying a new hair loss treatment, Ruxolitinib, alongside their existing regimen of finasteride, minoxidil, ketoconazole shampoo, and microneedling. They plan to apply Ruxolitinib to their temples daily for 1-2 months.
community KX-826 Pyrilutamide1% coming soon
KX-826 Pyrilutamide 1% is launching soon, and users are discussing its potential benefits and drawbacks compared to other treatments like Minoxidil and finasteride. Some users are skeptical about its effectiveness, while others are hopeful it will be a safer alternative.
community Exosomes increase by 46% the efficacy at 1 year of standard treatment for AAG using {Dutasteride 0.5mg/day + minoxidil 5mg/day}
Adding exosomes to a treatment of dutasteride and minoxidil for hair loss increased hair count by 55% at 6 months and 46% at 1 year compared to the control group. The control group did not receive exosomes or PRP.
community Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market?
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.